JP5788863B2 - 腫瘍開始細胞およびその使用方法 - Google Patents

腫瘍開始細胞およびその使用方法 Download PDF

Info

Publication number
JP5788863B2
JP5788863B2 JP2012502309A JP2012502309A JP5788863B2 JP 5788863 B2 JP5788863 B2 JP 5788863B2 JP 2012502309 A JP2012502309 A JP 2012502309A JP 2012502309 A JP2012502309 A JP 2012502309A JP 5788863 B2 JP5788863 B2 JP 5788863B2
Authority
JP
Japan
Prior art keywords
tumor
cells
cell population
initiating
enriched
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2012502309A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012521769A5 (cg-RX-API-DMAC7.html
JP2012521769A (ja
Inventor
イサック ダメリン マーク
イサック ダメリン マーク
ジー. ゲレス ケネス
ジー. ゲレス ケネス
ピー. ゴラス ジョナサン
ピー. ゴラス ジョナサン
ボガート アーウィン
ボガート アーウィン
エス.チョウ ビン−ビング
エス.チョウ ビン−ビング
Original Assignee
ワイス・エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ワイス・エルエルシー filed Critical ワイス・エルエルシー
Publication of JP2012521769A publication Critical patent/JP2012521769A/ja
Publication of JP2012521769A5 publication Critical patent/JP2012521769A5/ja
Application granted granted Critical
Publication of JP5788863B2 publication Critical patent/JP5788863B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C12N5/0695—Stem cells; Progenitor cells; Precursor cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/385—Hormones with nuclear receptors of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2012502309A 2009-03-27 2010-03-26 腫瘍開始細胞およびその使用方法 Expired - Fee Related JP5788863B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16427209P 2009-03-27 2009-03-27
US61/164,272 2009-03-27
PCT/US2010/028926 WO2010111659A1 (en) 2009-03-27 2010-03-26 Tumor-initiating cells and methods for using same

Publications (3)

Publication Number Publication Date
JP2012521769A JP2012521769A (ja) 2012-09-20
JP2012521769A5 JP2012521769A5 (cg-RX-API-DMAC7.html) 2013-05-23
JP5788863B2 true JP5788863B2 (ja) 2015-10-07

Family

ID=42332716

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012502309A Expired - Fee Related JP5788863B2 (ja) 2009-03-27 2010-03-26 腫瘍開始細胞およびその使用方法

Country Status (6)

Country Link
US (2) US9340774B2 (cg-RX-API-DMAC7.html)
EP (1) EP2411508B1 (cg-RX-API-DMAC7.html)
JP (1) JP5788863B2 (cg-RX-API-DMAC7.html)
CA (1) CA2754610C (cg-RX-API-DMAC7.html)
ES (1) ES2405605T3 (cg-RX-API-DMAC7.html)
WO (1) WO2010111659A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE031017T2 (en) 2011-04-01 2017-06-28 Wyeth Llc Antibody Drug Conjugates
WO2013068874A1 (en) 2011-11-11 2013-05-16 Pfizer Inc. Antibody-drug conjugates
US10254286B2 (en) 2012-01-24 2019-04-09 Pfizer Inc. Methods for detecting 5T4-positive circulating tumor cells and methods of diagnosis of 5T4-positive cancer in a mammalian subject
WO2013148147A1 (en) 2012-03-26 2013-10-03 The U.S.A., As Represented By The Secretary Dept. Of Health And Human Services Dna methylation analysis for the diagnosis, prognosis and treatment of adrenal neoplasms
US9551036B2 (en) * 2013-02-25 2017-01-24 Whitehead Institute For Biomedical Research Metabolic gene mesenchymal signatures and uses thereof
WO2016022939A1 (en) * 2014-08-08 2016-02-11 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Human monoclonal antibodies specific for 5t4 and methods of their use
US9476100B1 (en) * 2015-07-06 2016-10-25 Nucleix Ltd. Methods for diagnosing bladder cancer
KR20190105028A (ko) 2017-01-04 2019-09-11 내셔널 타이완 유니버시티 폐암 줄기 세포를 위한 바이오마커
EP3595705A1 (en) * 2017-03-15 2020-01-22 Oxford BioMedica (UK) Limited Method
CA3078791A1 (en) 2017-10-11 2019-04-18 Lunella Biotech, Inc. Anti-mitochondrial inhibitors for oncogenic ras and myc
US11189361B2 (en) 2018-06-28 2021-11-30 International Business Machines Corporation Functional analysis of time-series phylogenetic tumor evolution tree
US11211148B2 (en) 2018-06-28 2021-12-28 International Business Machines Corporation Time-series phylogenetic tumor evolution trees
IL265451B (en) 2019-03-18 2020-01-30 Frumkin Dan Methods and systems for the detection of methylation changes in DNA samples
CN114487418A (zh) 2022-02-17 2022-05-13 温州医科大学附属第二医院(温州医科大学附属育英儿童医院) TGFb RIII蛋白作为胃癌血清生物标志物的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869053A (en) 1988-03-04 1999-02-09 Cancer Research Campaign Technology, Ltd. 5T4 antigen from human trophoblasts
DE68923027D1 (de) 1988-03-04 1995-07-20 Cancer Res Campaign Tech Antigene.
US5736396A (en) 1995-01-24 1998-04-07 Case Western Reserve University Lineage-directed induction of human mesenchymal stem cell differentiation
US7700359B2 (en) * 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
GB0215287D0 (en) * 2002-07-02 2002-08-14 Oxford Biomedica Ltd 5T4 antigen expression
CA2578131A1 (en) 2004-09-10 2006-03-23 Wyeth Humanized anti-5t4 antibodies and anti-5t4 antibody/calicheamicin conjugates
EP1945754B1 (en) 2005-10-31 2014-07-23 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
SG170091A1 (en) 2006-03-10 2011-04-29 Wyeth Corp Anti-5t4 antibodies and uses thereof

Also Published As

Publication number Publication date
CA2754610A1 (en) 2010-09-30
US20160326496A1 (en) 2016-11-10
WO2010111659A8 (en) 2011-08-25
EP2411508B1 (en) 2013-03-20
WO2010111659A1 (en) 2010-09-30
US20120071350A1 (en) 2012-03-22
US9340774B2 (en) 2016-05-17
ES2405605T3 (es) 2013-05-31
JP2012521769A (ja) 2012-09-20
EP2411508A1 (en) 2012-02-01
CA2754610C (en) 2015-05-05

Similar Documents

Publication Publication Date Title
JP2012521769A (ja) 腫瘍開始細胞およびその使用方法
EP3826652B1 (en) Hepato-biliary-pancreatic tissues and methods of making same
JP7148552B2 (ja) 肝臓オルガノイド組成物ならびにその作製および使用方法
US20240368556A1 (en) Liver organoid model for hyperbilirubinemia and methods of making and using same
Zen et al. Histological and culture studies with respect to ABCG2 expression support the existence of a cancer cell hierarchy in human hepatocellular carcinoma
JP2022119862A (ja) 肝臓オルガノイド組成物ならびにその作製および使用方法
JP2024509353A6 (ja) 再プログラム可能なTnpBポリペプチド及びその使用
CN103328626B (zh) 癌干细胞群及其制备方法
US20170205396A1 (en) Systems and methods for culturing nephron progenitor cells
JP7399955B2 (ja) インビトロで肝細胞を増殖・培養する方法及び応用
JP2018057383A (ja) 大腸上皮幹細胞の単離・培養技術と、これを用いた大腸上皮移植技術
CN103459591A (zh) 肠细胞的制造方法
JP2013066414A (ja) 胃前駆細胞の表面マーカー
TW201639956A (zh) 人類纖維板層肝細胞癌(hFL-HCCs)
JP2015500637A (ja) 一倍体細胞
CN120898133A (zh) 涉及水通道蛋白-5(aqp5)的方法和用途
EP3123169A1 (en) Flattop (fltp) is a novel biomarker for beta cell maturation
JP7267562B2 (ja) 免疫調節作用を有する単球およびその使用方法
Moro Pancreatic cancer: investigation of the prognostic significance of tumor immunophenotype and establishment of a novel ex-vivo tissue slice culture system for drug sensitivity testing
JP2026513258A (ja) 臨床グレードのオルガノイド
Zook Characterization of Ductal Progenitor-Like Cells From the Adult Human Pancreas
Leroy Role of connexins, pannexins and their channels in liver cancer
Pickles Regulation of MHC Class II expression in colorectal cancer
Price Establishment of a gastrointestinal epithelial organoid assay to assess bowel toxicity in response to chemoradiation treatment
Namdar Feasibility of Direct Reprogramming of Myofibroblasts to Lung Epithelial Cells Utilizing PiggyBac Transposon System

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130325

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130325

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140909

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20140910

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141205

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141212

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150309

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150706

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150730

R150 Certificate of patent or registration of utility model

Ref document number: 5788863

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees